Cargando…

Identification and characterization of novel CD274 (PD‐L1) regulating microRNAs and their functional relevance in melanoma

BACKGROUND: Immune checkpoint inhibitors directed against programmed cell death 1 (PDCD1/PD1) receptor and programmed cell death‐ligand 1 (CD274/PD‐L1) have been recently successfully implemented for the treatment of many cancers, but the response rate of tumour patients is still limited due to intr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vaxevanis, Christoforos K., Friedrich, Michael, Tretbar, Sandy Uta, Handke, Diana, Wang, Yuan, Blümke, Juliane, Dummer, Reinhard, Massa, Chiara, Seliger, Barbara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270002/ https://www.ncbi.nlm.nih.gov/pubmed/35802807 http://dx.doi.org/10.1002/ctm2.934

Ejemplares similares

Identification of microRNAs Targeting the Transporter Associated with Antigen Processing TAP1 in Melanoma
por: Lazaridou, Maria-Filothei, et al.
Publicado: (2020)

TGF-β inducible epithelial-to-mesenchymal transition in renal cell carcinoma
por: Tretbar, Sandy, et al.
Publicado: (2019)

Relevance of 2′-O-Methylation and Pseudouridylation for the Malignant Melanoma
por: Jasinski-Bergner, Simon, et al.
Publicado: (2021)

Correlation of the tumor escape phenotype with loss of PRELP expression in melanoma
por: Schäfer, Helene, et al.
Publicado: (2023)

Characterizing CD44 regulatory microRNAs as putative therapeutic agents in human melanoma
por: Fänder, Johannes, et al.
Publicado: (2019)

Novel approach to identify putative Epstein–Barr–virus microRNAs regulating host cell genes with relevance in tumor biology and immunology
por: Jasinski-Bergner, Simon, et al.
Publicado: (2022)

Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients
por: Lazaridou, Maria-Filothei, et al.
Publicado: (2020)

Targeting the coding sequence: opposing roles in regulating classical and non-classical MHC class I molecules by miR-16 and miR-744
por: Friedrich, Michael, et al.
Publicado: (2020)

Role of signal transduction and microRNAs on the immunogenicity of melanoma cells
por: Meyer, Stefanie, et al.
Publicado: (2015)

Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy
por: Vaxevanis, Christoforos K., et al.
Publicado: (2022)

Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins
por: Bauer, Marcus, et al.
Publicado: (2020)

High PD-L1/CD274 Expression of Monocytes and Blood Dendritic Cells Is a Risk Factor in Lung Cancer Patients Undergoing Treatment with PD1 Inhibitor Therapy
por: Riemann, Dagmar, et al.
Publicado: (2020)

Anticancer Activity of Natural and Semi-Synthetic Drimane and Coloratane Sesquiterpenoids
por: Beckmann, Lorenz, et al.
Publicado: (2022)

Identification of novel microRNAs regulating HLA-G expression and investigating their clinical relevance in renal cell carcinoma
por: Jasinski-Bergner, Simon, et al.
Publicado: (2016)

Quantifying the contribution of transcription factor activity, mutations and microRNAs to CD274 expression in cancer patients
por: Bruns, Imke B., et al.
Publicado: (2022)

Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA
por: Zhang, Wenxin, et al.
Publicado: (2023)

Histopathological and genotypic characterization of metastatic colorectal carcinoma with PD‐L1 (CD274)‐expression: Possible roles of tumour micro environmental factors for CD274 expression
por: Inaguma, Shingo, et al.
Publicado: (2017)

Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma
por: Du, Ziming, et al.
Publicado: (2014)

MicroRNAs affecting the susceptibility of melanoma cells to CD8(+) T cell‐mediated cytolysis
por: Pane, Antonino A., et al.
Publicado: (2023)

Relationship of PD-1 (PDCD1) and PD-L1 (CD274) Single Nucleotide Polymorphisms with Polycystic Ovary Syndrome
por: Han, Rui, et al.
Publicado: (2021)

Health Tract, No. 274: Bodily Strength
Publicado: (1867)

Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy
por: Fabrizio, Federico Pio, et al.
Publicado: (2018)

PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma
por: Klümper, Niklas, et al.
Publicado: (2023)

Distinct Molecular Mechanisms of Altered HLA Class II Expression in Malignant Melanoma
por: Meyer, Stefanie, et al.
Publicado: (2021)

HLA-G-specific microRNAs a novel approach for targeting tumors
por: Jasinski-Bergner, Simon, et al.
Publicado: (2013)

Flare-Up of Rheumatoid Arthritis by Anti-CTLA-4 Antibody but Not by Anti-PD1 Therapy in a Patient with Metastatic Melanoma
por: Jaberg-Bentele, Nicoletta F., et al.
Publicado: (2017)

Altered Spatial Composition of the Immune Cell Repertoire in Association to CD34(+) Blasts in Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia
por: Bauer, Marcus, et al.
Publicado: (2021)

Characterisation of tumor microenvironment and prevalence of CD274/PD-L1 genetic alterations difference in colorectal Cancer
por: Yang, Lin, et al.
Publicado: (2023)

The Epitope-Specific Anti-human CD4 Antibody MAX.16H5 and Its Role in Immune Tolerance
por: Stahl, Lilly, et al.
Publicado: (2019)

PSUN274 Chlorthalidone-Induced Diabetic Ketoacidosis.
por: Zafar, Rafia, et al.
Publicado: (2022)

PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas
por: Franzen, Alina, et al.
Publicado: (2017)

The Roles of MiRNAs (MicroRNAs) in Melanoma Immunotherapy
por: Dong, Linyinxue, et al.
Publicado: (2022)

Targeted treatment of advanced NRAS-mutated melanoma
por: Koelblinger, Peter, et al.
Publicado: (2017)

CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity
por: Straub, Melanie, et al.
Publicado: (2016)

Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis
por: Kim, Jong Yeob, et al.
Publicado: (2019)

Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages
por: Lai, Chun-Yi, et al.
Publicado: (2021)

Relationship of tumor PD‐L1 (CD274) expression with lower mortality in lung high‐grade neuroendocrine tumor
por: Inamura, Kentaro, et al.
Publicado: (2017)

PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker
por: Guo, Lei, et al.
Publicado: (2016)

Association of PIK3CA mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma
por: Ugai, Tomotaka, et al.
Publicado: (2021)

IGH::CD274 (PD‐L1) rearrangement in diffuse large B cell lymphoma and its therapeutic implication
por: Wu, Xuemei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8sv12an9ssl8dc9gcpl4c76iq9